Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06001788 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Acute Myeloid Leukemia and Leukemia, sponsored by Kura Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT06001788: Recruiting Phase 1 study of Acute Myeloid Leukemia and Leukemia, sponsored by Kura Oncology.
NCT06001788 is a Phase 1 study of Acute Myeloid Leukemia and Leukemia that is actively recruiting participants, run by Kura Oncology. The registered enrollment target is 171 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06001788, a Phase 1 study of Acute Myeloid Leukemia and Leukemia, is actively recruiting participants, sponsored by Kura Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Primary Outcome
Assessed by the NCI-CTCAE v5.0
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Gilteritinib
- DRUG Ziftomenib
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- UCLA Health - Bowyer Oncology Center - Los Angeles
- UC Irvine Health Chao Family Comprehensive Cancer Center - Orange
- University of California San Francisco - San Francisco
Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago
- Loyola University Medical Center - Maywood
- Simmons Cancer Institute - Springfield
Georgia
- Emory Healthcare - The Emory Clinic - Atlanta
- Georgia Cancer Center at Augusta University - Augusta
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Cancer Institute - Detroit
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT06001788 shows while recruiting
NCT06001788 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (49% higher).
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT06001788 names 20 study sites across 13 states, led by California, Illinois, Georgia.
Frequently Asked Questions
What is clinical trial NCT06001788 about?
NCT06001788 is a clinical study titled "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia". The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
What is the current status of trial NCT06001788?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2024-02-22. Estimated completion is 2027-08.
What conditions does trial NCT06001788 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Leukemia, Hematologic Malignancy, Leukemia, Myeloid, Acute, AML.
What interventions are being tested in trial NCT06001788?
The interventions under investigation include: Fludarabine (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), Gilteritinib (DRUG), Ziftomenib (DRUG).
Who is sponsoring clinical trial NCT06001788?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06001788 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06001788's enrollment target sits among peer trials
171 53rd of 306 higher than 254 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI